NZ510991A - Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders - Google Patents

Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders

Info

Publication number
NZ510991A
NZ510991A NZ510991A NZ51099198A NZ510991A NZ 510991 A NZ510991 A NZ 510991A NZ 510991 A NZ510991 A NZ 510991A NZ 51099198 A NZ51099198 A NZ 51099198A NZ 510991 A NZ510991 A NZ 510991A
Authority
NZ
New Zealand
Prior art keywords
formulations
cell proliferative
proliferative disorders
prevention
treatment
Prior art date
Application number
NZ510991A
Other languages
English (en)
Inventor
Narmada Shenoy
Gregory S Wagner
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Priority to NZ521773A priority Critical patent/NZ521773A/en
Publication of NZ510991A publication Critical patent/NZ510991A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
NZ510991A 1997-03-05 1998-03-04 Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders NZ510991A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ521773A NZ521773A (en) 1997-03-05 1998-03-04 Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3987097P 1997-03-05 1997-03-05
US4125197P 1997-03-18 1997-03-18

Publications (1)

Publication Number Publication Date
NZ510991A true NZ510991A (en) 2002-11-26

Family

ID=26716539

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ510991A NZ510991A (en) 1997-03-05 1998-03-04 Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders

Country Status (10)

Country Link
US (2) US6248771B1 (enExample)
EP (1) EP1014953B1 (enExample)
JP (1) JP4713698B2 (enExample)
AT (1) ATE554750T1 (enExample)
AU (1) AU743024B2 (enExample)
CA (1) CA2282439C (enExample)
CO (1) CO4940469A1 (enExample)
ES (1) ES2384551T3 (enExample)
NZ (1) NZ510991A (enExample)
WO (1) WO1998038984A2 (enExample)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6846839B1 (en) 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
DK2020408T3 (da) 1998-05-29 2013-09-30 Sugen Inc Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000056338A1 (en) * 1999-03-19 2000-09-28 Parker Hughes Institute Quinazoline formulations and therapeutic use thereof
US7064114B2 (en) 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations
EP1169054B1 (en) * 1999-04-09 2004-08-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Prognosis of ptp lar related diseases
ES2292461T3 (es) * 1999-07-07 2008-03-16 Astrazeneca Uk Limited Derivados de quinazolina.
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
DE60030164T2 (de) * 1999-12-30 2007-08-30 Sugen, Inc., San Francisco 3-Heteroarylidenyl-2-Indolinon Derivate für die Modulierung der Aktivität einer Proteinkinase und für die Verwendung bei der Chemotherapie von Krebs
PT1255752E (pt) 2000-02-15 2007-10-17 Pharmacia & Upjohn Co Llc Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1294688A2 (en) 2000-06-02 2003-03-26 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
WO2002000644A1 (en) 2000-06-24 2002-01-03 Astrazeneca Ab Guanidine derivatives of quinazoline and quinoline for use in the treatment of autoimmune diseases
AU2002216758A1 (en) * 2000-07-03 2002-01-14 Astrazeneca Ab Quinazolines with therapeutic use
AU7709901A (en) * 2000-07-24 2002-02-05 Upjohn Co Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilicdrugs
WO2002013762A2 (en) * 2000-08-10 2002-02-21 Delsys Pharmaceutical Corporation Improved solid pharmaceutical dosage formulation of hydrophobic drugs
WO2002030466A2 (en) * 2000-10-11 2002-04-18 Purdue Research Foundation Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof
US20050158271A1 (en) * 2000-10-11 2005-07-21 Lee Sang C. Pharmaceutical applications of hydrotropic polymer micelles
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2002069936A2 (en) * 2001-03-02 2002-09-12 Dr. Reddy's Laboratories Ltd. Pharmaceutical composition of ibuprofen
US6912582B2 (en) 2001-03-30 2005-06-28 Microsoft Corporation Service routing and web integration in a distributed multi-site user authentication system
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US6720002B2 (en) * 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
BR0214357A (pt) * 2001-11-21 2004-09-14 Sugen Inc Formulações farmacêuticas compreendendo derivados de indolinona
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
KR20040085151A (ko) * 2002-01-17 2004-10-07 뉴로젠 코포레이션 캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체
MXPA04006992A (es) * 2002-02-15 2004-11-10 Upjohn Co Procedimiento para preparar derivados de indolinona.
IL163642A0 (en) * 2002-02-26 2005-12-18 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
EA007987B1 (ru) * 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
MXPA04010539A (es) 2002-04-26 2005-01-25 Nippon Shinyaku Co Ltd Derivados de quinazolina y medicamentos que los contienen.
KR20050084292A (ko) * 2002-12-13 2005-08-26 뉴로젠 코포레이션 캅사이신 수용체 조절체로서 2-치환된 퀴나졸린-4-일아민동족체
ITRM20030074A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Formulazioni semisolide a rilascio immediato intese
WO2004087153A2 (en) * 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
WO2004091625A1 (en) 2003-04-16 2004-10-28 F. Hoffmann-La Roche Ag (6-(phenoxy)-pyrido`3,4-d! pyrimidin-2-yl)-amine derivatives as p38 kinase inhibitors for the treatment of inflammatoryy conditions such as rheumatois artritis
MXPA05011103A (es) 2003-04-16 2005-12-12 Hoffmann La Roche Compuestos de quinazolina.
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
US7329664B2 (en) * 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
DK1667991T3 (da) 2003-09-16 2008-08-18 Astrazeneca Ab Quinazolinderivater som tyrosinkinaseinhibitorer
ES2327418T3 (es) * 2003-10-16 2009-10-29 Novartis Vaccines And Diagnostics, Inc. Benzazoles sustituidos y uso de los mismos como inhibidores de la quinasa raf.
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US7491263B2 (en) 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
EP1746999B1 (en) 2004-05-06 2011-11-16 Warner-Lambert Company LLC 4-phenylamino-quinazolin-6-yl-amides
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
CA2569763C (en) 2004-06-08 2013-03-12 Decode Chemistry, Inc. 2,4-diaminoquinazolines for spinal muscular atrophy
RU2382034C2 (ru) * 2004-11-09 2010-02-20 Ф.Хоффманн-Ля Рош Аг Соединения аминохиназолинов
DE602005026865D1 (de) 2004-12-14 2011-04-21 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
US8673351B2 (en) * 2005-03-21 2014-03-18 Ivax Pharmaceuticals S.R.O. Crystallization inhibitor and its use in gelatin capsules
EP1928861B1 (en) 2005-09-20 2010-11-17 AstraZeneca AB 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
JP2009528365A (ja) * 2006-02-28 2009-08-06 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのシンノリン及びキナゾリン誘導体
WO2008016973A1 (en) 2006-08-01 2008-02-07 Families Of Spinal Muscular Atrophy 2,4-diaminoquinazolines for spinal muscular atrophy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
EP2245026B1 (de) 2008-02-07 2012-08-01 Boehringer Ingelheim International GmbH Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2009114365A2 (en) * 2008-03-13 2009-09-17 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
AU2009247782C1 (en) 2008-05-13 2013-09-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
JP5359333B2 (ja) * 2009-02-05 2013-12-04 ゼリア新薬工業株式会社 コロソリン酸含有水性液剤
PL2401267T3 (pl) * 2009-02-27 2014-06-30 Ambit Biosciences Corp Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
EP3575288B1 (en) 2009-09-03 2021-10-27 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
ES2727733T3 (es) * 2009-11-10 2019-10-18 Celgene Corp Nanosuspensión de un fármaco poco soluble preparada por el proceso de microfluidización
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN102716103B (zh) * 2012-07-02 2013-12-18 西安力邦制药有限公司 2,2′,6,6′-四异丙基-4,4′-二联苯酚软胶囊制剂及其制备方法
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN103837615B (zh) * 2014-02-15 2015-05-20 青岛农业大学 一种应用高效液相色谱法同时测定植物蜕皮激素类物质的方法
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
CA3138123A1 (en) 2019-05-13 2020-11-19 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CA3180971A1 (en) * 2020-04-22 2021-10-28 Scienture, Inc. Long-acting bupivacaine microsphere formulations
CN113398067B (zh) * 2021-07-19 2022-08-16 宁波三生生物科技股份有限公司 一种四烯雌酮注射液及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3970725A (en) 1972-09-26 1976-07-20 Dai Nippon Toryo Co., Ltd. Powdery coating composition and process for preparing the same
US3850939A (en) 1973-02-20 1974-11-26 Parke Davis & Co 5-nitro-2-thiazolylthiopyridine,1-oxides
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
JPS59190967A (ja) * 1983-04-15 1984-10-29 Hokuriku Seiyaku Co Ltd １−（２，６−ジフルオロフエニル）−２−インドリノン誘導体
JPS61167616A (ja) * 1985-01-22 1986-07-29 Adeka Argus Chem Co Ltd 放射線増感剤
EP0448841B1 (en) 1990-03-19 1993-06-02 Agfa-Gevaert N.V. Photographic materials containing electron accepting agents
EP0548250B1 (en) 1990-09-10 1996-03-27 Rhone-Poulenc Rorer International (Holdings) Inc. Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5314685A (en) 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
JPH11507052A (ja) * 1995-06-07 1999-06-22 スージェン・インコーポレーテッド キナゾリンおよび医薬組成物
WO1996040113A2 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Phosphatase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5763470A (en) * 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity

Also Published As

Publication number Publication date
ATE554750T1 (de) 2012-05-15
WO1998038984A3 (en) 1999-01-28
CO4940469A1 (es) 2000-07-24
US6696482B2 (en) 2004-02-24
ES2384551T3 (es) 2012-07-06
US20010012844A1 (en) 2001-08-09
JP4713698B2 (ja) 2011-06-29
US6248771B1 (en) 2001-06-19
HK1028548A1 (en) 2001-02-23
AU743024B2 (en) 2002-01-17
WO1998038984A2 (en) 1998-09-11
EP1014953A2 (en) 2000-07-05
JP2001514626A (ja) 2001-09-11
CA2282439C (en) 2010-05-04
AU6680698A (en) 1998-09-22
CA2282439A1 (en) 1998-09-11
EP1014953B1 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
NZ510991A (en) Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
TNSN97114A1 (fr) Granule pour la preparation des compositions a desintegration et dissolution rapides comprenant une teneur elevee d'un principe actif
FR2405711A1 (fr) Composition pharmaceutique contenant de l'amoxycilline et du clavulanate de potassium
MY125556A (en) Aqueous formulations of peptide
ES2145158T3 (es) Nueva formulacion de emulsion.
NZ513810A (en) Compositions and methods for improved delivery of hydrophobic therapeutic agents
CL2009001870A1 (es) Composicion farmaceutica que comprende: a) un agente activo de prostaglandina que es 13,14-dihidro-15-ceto-20-etil-pgf2alfa isopropil ester, b) un primer tensoactivo no ionico, c) un segundo tensoactivo no ionico, d) un vehiculo oftalmicamente aceptable, util en el tratamiento de la hipertension ocular (divisional de la solicitud 557-98).
BR0109779A (pt) Soluções moleculares hidrofìlicas dispersas de carvedilol
IL117889A0 (en) Pharmaceutical compositions containing lipophilic compounds
ES2184310T3 (es) Formulacion autoemulsionante para compuestos lipofilos acidos.
AU2001288460A1 (en) Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
IL151311A0 (en) Pharmaceutical compositions containing propofol
AR003545A1 (es) Composiciones de limpieza liquida espesa, viscoelastica; metodo para su uso
ATE253820T1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
PL311637A1 (en) Poured over preparations containing a polymer as well as glycerides and glycols
KR970064617A (ko) 치주질환 예방 및 치료제 조성물
KR930001903A (ko) 유비데카레논 경구용 수용액 제제
KR950031084A (ko) 국소용 진양(鎭洋) 조성물
AU3777197A (en) Cyclosporin formulation
AU2809697A (en) Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
ZA969351B (en) Organic compositions
NZ521533A (en) Veterinary compositions for the treatment of parasitic diseases containing rafoxanide
CA2266898A1 (en) Intranasal formulations for promoting sleep and method of using the same

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
S35A Application for proceedings under section 35 (restoration of lapsed patents)
RENW Renewal (renewal fees accepted)
S35R Proceedings under section 35 (restoration of lapsed patents): patent restored
RENW Renewal (renewal fees accepted)
EXPY Patent expired